We are pleased to announce the appointments of Dong Kim, MBA, as Chief Business Officer, and Jeff Kang, CPA, as Chief Financial Officer. Dong brings 20 years of business development, strategy and finance experience in the biopharmaceutical industry, most recently as head of business development at Mirum Pharmaceuticals and at Aduro Biotech. Jeff has 20+ years of experience in the financial industry and at start-ups as an equity analyst and CFO leading financial strategy and corporate finance, most recently as CFO at Cellatoz Therapeutics and previously at Kurly. At GenEdit, Dong will advance our strategy of building a pipeline of partnered and wholly-owned therapeutic candidates, and Jeff will lead financial efforts to support our continued growth. See more here: https://genedit.com/about/ #geneticmedicines #NanoGalaxy #autoimmunedisease #cancer #oncology #immunology #mRNA #siRNA #immunooncology #nucleicacid #nanoparticle
GenEdit
生物技术研究
South San Francisco，California 3,133 位关注者
Delivering the potential of genetic medicines
关于我们
GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.
- 网站
-
https://www.GenEdit.com
GenEdit的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
- 创立
- 2016
地点
-
主要
获取路线
681 Gateway Blvd
Suite 313
US，California，South San Francisco，94080
GenEdit员工
动态
-
We are pleased to announce the appointment of J. Rodrigo Mora, MD, PhD, as Chief Scientific Officer at GenEdit. Dr. Mora has over 25 years of experience in immunology research and drug development, including holding pivotal executive and scientific leadership roles at Moderna, Takeda, and Janssen. At GenEdit, Dr. Mora will lead the advancement of the company’s ongoing R&D programs to develop novel therapeutics for neurology and new R&D programs to develop therapeutics for immunology and immuno-oncology. Read more about Dr. Mora’s role at GenEdit: https://lnkd.in/gAp5YiVr #geneticmedicines #NanoGalaxy #autoimmunedisease #cancer #oncology #immunology
-
-
GenEdit is expanding!??? We're thrilled to announce our move to a larger, state-of-the-art facility at the Genesis-Marina life sciences development in the heart of the South San Francisco biotech hub. We are incredibly grateful to Eli Lilly and Company for their support during our time at the Lilly Gateway Labs and are excited about our new home with the space and resources to accelerate our growth and innovation. We can't wait to welcome you and continue pushing the boundaries of what's possible in the life sciences! #GenEdit #NewHQ #GenesisMarina #LifeSciences #SouthSanFrancisco #Biotech #Growth #Innovation
-
-
Interested in hearing more about Genedit at #BIO2024? I will present GenEdit at the Company Presentation Theater 3 session on Monday June 3rd at 12:45 pm. Let's connect in the BIO One-on-One Partnering system. See you in San Diego.
-
Congratulations to Editas Medicine for the?new status?of RUBY as a Phase 1/2/3 trial! With the potential to revolutionize treatment for sickle cell anemia patients, Reni-cel represents a significant advancement in medical innovation. This milestone is also exciting for GenEdit because Reni-cel incorporates our cutting-edge technologies licensed to Editas.